51. Association between mortality and cardiovascular diseases in the vulnerable Mexican population: A cross-sectional retrospective study of the COVID-19 pandemic
- Author
-
Gerardo R. Padilla-Rivas, Juan Luis Delgado-Gallegos, Gerardo Garza-Treviño, Kame A. Galan-Huerta, Zuca G-Buentello, Jorge A. Roacho-Pérez, Michelle Giovana Santoyo-Suarez, Hector Franco-Villareal, Ahidée Leyva-Lopez, Ana E. Estrada-Rodriguez, Jorge E. Moreno-Cuevas, Javier Ramos-Jimenez, Ana M. Rivas-Estrilla, Elsa N. Garza-Treviño, and Jose Francisco Islas
- Subjects
cardiovascular diseases ,Mexico COVID-19 ,México metropolitan area ,COVID-CVDs ,COVID mortality in Mexico ,Public aspects of medicine ,RA1-1270 - Abstract
Cardiovascular diseases (CVDs) continue to be the leading cause of death worldwide. Over the past couple of years and with the surge of the COVID-19 pandemic, mortality from CVDs has been slightly overshadowed by those due to COVID-19, although it was during the peak of the pandemic. In the present study, patients with CVDs (CVDs; n = 41,883) were analyzed to determine which comorbidities had the largest impact on overall patient mortality due to their association with both diseases (n = 3,637). Obesity, hypertension, and diabetes worsen health in patients diagnosed positive for COVID-19. Hence, they were included in the overview of all patients with CVD. Our findings showed that 1,697 deaths were attributable to diabetes (p < 0.001) and 987 deaths to obesity (p < 0.001). Lastly, 2,499 deaths were attributable to hypertension (p < 0.001). Using logistic regression modeling, we found that diabetes (OR: 1.744, p < 0.001) and hypertension (OR: 2.179, p < 0.001) significantly affected the mortality rate of patients. Hence, having a CVD diagnosis, with hypertension and/or diabetes, seems to increase the likelihood of complications, leading to death in patients diagnosed positive for COVID-19.
- Published
- 2022
- Full Text
- View/download PDF